Strategic Diagnostics announces success in demonstrating utility of its proprietary Genomic Antibodies reagents on clinical samples in cooperation with the Human Protein Atlas
The reagents, produced using SDI's proprietary Genomic Antibodies technology, specifically target a selection of cancer associated proteins.
The antibodies were studied in the HPA's tissue-profiling program and generated high-resolution immunohistochemistry images across a wide spectrum of normal and cancerous tissues.
Analyses of immunohistochemistry images are standard tests performed by pathology laboratories to diagnose disease.
For each antibody, 576 spots of human tissue from 360 different individuals were treated and stained.
Images created in the analysis clearly demonstrated the ability of antibodies generated by SDI's high throughput Genomic Antibodies technology to differentially stain cancer-associated proteins in patient tissue samples.
The antibodies are created by using a proprietary system that produces recombinant protein inside the host animal, thereby activating an immune response to the encoded protein.
This allows the production of antibodies generated against the protein's native structure, rather than traditional methods that produce antibodies to synthesised surrogates.
Among the advantages of the Genomic Antibodies technology is its ability to enable the development of reagents against traditionally difficult cellular targets, such as highly conserved and transmembrane proteins.
The system is highly scaleable, allowing the generation of custom libraries consisting of hundreds of antibodies for use in the drug discovery, diagnostic, and research markets.
SDI is currently developing a significant number of these innovative reagents to be offered via a web-based catalogue.
Matthew Knight, the company's president and chief executive officer, commented: "The demonstrated advantages of our Genomic Antibodies technology continue to produce real-world data to differentiate our antibody reagents from antibody reagents generated by traditional means.
"The HPA data is more evidence that our antibodies can perform under rigorous study conditions".
Strategic Diagnostics offers custom service access to its Genomic Antibodies technology for polyclonal and monoclonal products.
